Skip to main content

Advertisement

SpringerLink
Log in

Observations with Depo-Provera (medroxyprogesterone) in the management of renal tumours

  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

A total of 30 patients with renal tumours were started on Depo-Provera (medroxyprogesterone) in December 1981 and followed up for 17 to 44 months. The survivors were checked in July 1985. In 2 of the 13 metastasis-free patients deposits of lethal outcome had formed, survival time averaging 27 months. One of the 8 patients with local metastases had died of renal tumour, average survival time being 26 months.

Among the 9 patients with distant metastases there are 2 with survival times of 42 and 44 months, respectively. The liver metastases confirmed by ultrasonography in the first, and in the vena cava in the second case at the time of surgery are no longer demonstrable. Survival time in the last-named group averages 14.5 months.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bloom, H. J. G.: Hormone-induced and spontaneous regression of metastatic renal cancer.Cancer, 32, 106 (1983).

    Google Scholar 

  2. Cummings, K. B., Wheelis, R. F., Nelson, F. W.: Role of hormones in growths kinetics of renal cell carcinoma in vitro.J. Urol., 117, 269 (1977).

    PubMed  CAS  Google Scholar 

  3. Luderer, R. C., Opripari, M. J., Perrotta, A. L.: Treatment of metastatic renal cell carcinoma.J. Am. Osteopath. Assoc., 77, 590 (1978).

    PubMed  CAS  Google Scholar 

  4. Papac, K. J., Ross, A. S., Levy, A.: Renal cell carcinoma: analysis of 31 cases with assessment of endocrine therapy.Am. J. Med. Sci., 274, 281 (1977).

    Article  PubMed  CAS  Google Scholar 

  5. Samuels, M. L., Sullivan, P., Howe, C. D.: Medroxyprogesterone acetate in the treatment of renal cell carcinoma (hypernephroma).Cancer, 22, 525 (1968).

    Article  PubMed  CAS  Google Scholar 

  6. Spiers, A. S. D.: Chemotherapy and Urological Malignancy. Springer Verlag. Berlin-Heidelberg-New York 1982, p. 15.

    Google Scholar 

  7. Wagle, D. G., Murphy, G. P.: Hormonal therapy in advanced renal carcinoma.Cancer, 28, 38 (1971).

    Article  Google Scholar 

  8. Wallace, S., Chuang, V., Swangson, S., Bracken, B., Hersh, E. M., Eschenbach, A., Johnson, D.: In: Taylor, R. V. (ed.): Progesterones in the Management of Hormone Responsive Carcinomas. The Medicine Publishing Foundation, Oxford 1980, [. 62.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Semmelweis University Medical School, Budapest, Hungary

    I. Romics & D. Répássy

Authors
  1. I. Romics
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Répássy
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Romics, I., Répássy, D. Observations with Depo-Provera (medroxyprogesterone) in the management of renal tumours. International Urology and Nephrology 19, 49–54 (1987). https://doi.org/10.1007/BF02549677

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02549677

Keywords

Search

Navigation